141 related articles for article (PubMed ID: 9509253)
1. Detection of minimal residual disease: relevance for diagnosis and treatment of human malignancies.
Hirsch-Ginsberg C
Annu Rev Med; 1998; 49():111-22. PubMed ID: 9509253
[TBL] [Abstract][Full Text] [Related]
2. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease post-bone marrow transplantation for hemato-oncological diseases.
Toren A; Rechavi G; Nagler A
Stem Cells; 1996 May; 14(3):300-11. PubMed ID: 8724696
[TBL] [Abstract][Full Text] [Related]
4. Detection of minimal residual disease in patients with cancer: a review of techniques, clinical implications, and emerging therapeutic consequences.
Köstler WJ; Brodowicz T; Hejna M; Wiltschke C; Zielinski CC
Cancer Detect Prev; 2000; 24(4):376-403. PubMed ID: 11059569
[TBL] [Abstract][Full Text] [Related]
5. Purging of peripheral blood stem cell transplants in AML: a predictive model based on minimal residual disease burden.
Feller N; Jansen-van der Weide MC; van der Pol MA; Westra GA; Ossenkoppele GJ; Schuurhuis GJ
Exp Hematol; 2005 Jan; 33(1):120-30. PubMed ID: 15661405
[TBL] [Abstract][Full Text] [Related]
6. Fluorescent in situ hybridization on flow-sorted cells as a tool for evaluating minimal residual disease or chimerism after allogenic bone marrow transplantation.
Cotteret S; Belloc F; Boiron JM; Bilhou-Nabera C; Dumain P; Boyer C; Lacombe F; Reiffers J; Bernard P
Cytometry; 1998 Oct; 34(5):216-22. PubMed ID: 9822307
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer.
Diel IJ; Cote RJ
Cancer Treat Rev; 2000 Feb; 26(1):53-65. PubMed ID: 10660491
[TBL] [Abstract][Full Text] [Related]
8. Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioView (Duet) combined morphological and cytogenetical analysis.
Shimoni A; Nagler A; Kaplinsky C; Reichart M; Avigdor A; Hardan I; Yeshurun M; Daniely M; Zilberstein Y; Amariglio N; Brok-Simoni F; Rechavi G; Trakhtenbrot L
Leukemia; 2002 Aug; 16(8):1413-8; discussion 1419-22. PubMed ID: 12145678
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications of minimal residual disease monitoring for stem cell transplantation after reduced intensity and nonmyeloablative conditioning.
Shimoni A; Nagler A
Acta Haematol; 2004; 112(1-2):93-104. PubMed ID: 15179009
[TBL] [Abstract][Full Text] [Related]
10. Detection of numerical aberrations in hematologic neoplasias by fluorescence in situ hybridization.
Cuneo A; Bigoni R; Roberti MG; Bardi A; Balsamo R; Piva N; Castoldi G
Haematologica; 1997; 82(1):85-90. PubMed ID: 9107092
[TBL] [Abstract][Full Text] [Related]
11. [Significance of minimal residual disease for the estimation of the prognosis and for therapeutic decisions in solid tumors].
Hinterberger W; Buxhofer V; Ogris E; Zelenka P; Kier P; Ruckser R; Dorner S; Habertheuer KH; Vedovelli H; Schindler S; Hinterberger-Fischer M
Acta Med Austriaca Suppl; 2002; 59():2-8. PubMed ID: 12506753
[TBL] [Abstract][Full Text] [Related]
12. [Minimal residual disease in gastrointestinal tumors: tumor detection in bone marrow, blood and lymph nodes].
Rosenberg R; Nekarda H; Thorban S; Siewert JR
Acta Med Austriaca Suppl; 2002; 59():42-53. PubMed ID: 12506760
[TBL] [Abstract][Full Text] [Related]
13. [Diagnosis and significance of minimal residual disease in patients with colorectal carcinoma].
von Knebel Doeberitz M; Koch M; Weitz J; Herfarth C
Zentralbl Chir; 2000; 125 Suppl 1():15-9. PubMed ID: 10929641
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.
Björklund E; Mazur J; Söderhäll S; Porwit-MacDonald A
Leukemia; 2003 Jan; 17(1):138-48. PubMed ID: 12529671
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Wang YP; Chen J
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):6-9. PubMed ID: 15946500
[TBL] [Abstract][Full Text] [Related]
16. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.
Hämäläinen MM; Kairisto V; Juvonen V; Johansson J; Aurén J; Kohonen K; Remes K; Salmi TT; Helenius H; Pelliniemi TT
Eur J Haematol; 2008 Mar; 80(3):201-7. PubMed ID: 18081724
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease: detection, clinical relevance, and treatment strategies.
Dwenger A; Lindemann A; Mertelsmann R
J Hematother; 1996 Oct; 5(5):537-48. PubMed ID: 8938526
[TBL] [Abstract][Full Text] [Related]
18. Polymerase chain reaction in the detection of micrometastases and circulating tumor cells.
Ghossein RA; Rosai J
Cancer; 1996 Jul; 78(1):10-6. PubMed ID: 8646704
[TBL] [Abstract][Full Text] [Related]
19. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.
Korthals M; Sehnke N; Kronenwett R; Schroeder T; Strapatsas T; Kobbe G; Haas R; Fenk R
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1109-15. PubMed ID: 23644045
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterisation of minimal residual disease in solid tumors.
Pantel K; Otte M
Acta Med Austriaca Suppl; 2000; 52():8-12. PubMed ID: 11261279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
